Flunarizine, a Calcium Channel Blocker: a New Prophylactic Drug in Migraine




The postulated pivotal role of focal brain hypoxia in the genesis of the migraine attack and the anti-hypoxic properties of flunarizine, have led to the use of the selective calcium-entry blocker in the treatment of migraine. Clinical experience is reviewed. Open findings, confirmed by double-blind placebo-controlled studies and comparisons with pizotifen and cinnarizine, have shown that flunarizine, given at 10 mg daily, is a safe and effective prophylactic drug for both common and classical migraine. Factors determining the efficacy of flunarizine are discussed.